HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

Q3 2017 13F Holders as of 30 Sep 2017

Type / Class
Equity / Common Stock
Shares outstanding
123,650,000
Total 13F shares
121,459,215
Share change
-347,372
Total reported value
$2,109,824,400
Put/Call ratio
12%
Price per share
$17.37
Number of holders
164
Value change
-$3,483,727
Number of buys
81
Number of sells
66

Institutional Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q3 2017

As of 30 Sep 2017, HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) was held by 164 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 121,459,215 shares. The largest 10 holders included Third Security, LLC, BlackRock Inc., IRIDIAN ASSET MANAGEMENT LLC/CT, VANGUARD GROUP INC, BB BIOTECH AG, First Eagle Investment Management, LLC, FMR LLC, Invesco Ltd., SENZAR ASSET MANAGEMENT, LLC, and STATE STREET CORP. This page lists 164 institutional shareholders reporting positions in this security for the Q3 2017 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.